BNT162b2 vaccine

Phase 3Vaccine

BioNTech

BNT162b2 vaccine is one of 17 biologic programs targeting COVID-19. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Unknown status

COVID-19 VaccineRecruiting

COVID-19Phase 3

Unknown status

COVID-19 VaccinePhase 3

Recruiting

Competition

Competitive Landscape

317 competitors in COVID-19

#DrugCompanyPhaseTrials

BNT162b2 vaccine

BioNTech

Phase 3

6 2

Blood Taken

HHospices Civils de Lyon

Preclinical

1 3

Other Tkis

Bayer

Preclinical

1 4

Serology

UUniversity Hospital Center of Martinique

Preclinical

3 5

Pfizer-Biontech COVID-19 MRNA Vaccine

Pfizer

Preclinical

1 6

Administration of Almitrine

CCentre Hospitalier Universitaire de Nice

Preclinical

1 7

Tpa

UUniversity of Florida

Preclinical

1 8

Thrombolytic

FFaculty Hospital Kralovske Vinohrady

Preclinical

1 9

Coronavac COVID-19 Vaccine

HHospital Moinhos de Vento

Preclinical

2 10

SARS-Cov-2 Bivalent MRNA Vaccine

AAIM Vaccine Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

ApprovedRecruiting

COVID-19 Vaccine

NCT07730450

Clinical

Trials by Indication[1]

COVID-196 trials

COVID-19 3rd Dose Vaccine in Transplant Patients

Terminated·GGiselle Guerra·Phase 3·NCT05047640·58 enrolled

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

Recruiting· BioNTech logo

BioNTech·Phase 3·NCT07300839·25,500 enrolled

Fourth BNT162b2 COVID-19 Vaccine Dose

Unknown status·SSheba Medical Center·Phase 4·NCT05231005·1,000 enrolled

Show 3 more trials

Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong

Completed·HHong Kong Sanatorium & Hospital··NCT04898946·480 enrolled

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

Unknown status·VVaxxinity, Inc.·Phase 3·NCT05293665·944 enrolled

COVID-19 Protection After Transplant Pilot Study

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04969263·81 enrolled

Trial1 trial

Booster Dose Trial

Terminated·MMontefiore Medical Center·Phase 2·NCT05016622·106 enrolled

COVID-19 Vaccine1 trial

A PHASE 4, RANDOMIZED, DOUBLE-BLIND, THIRD-PARTY-UNBLINDED STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF A BNT162B2 RNA-BASED, VARIANT-ADAPTED VACCINE CANDIDATE AGAINST SARS-COV-2 AND EVALUATE THE CIRCULATING SARS-COV-2 SPIKE PROTEIN LEVEL IN HEALTHY PARTICIPANTS 18 THROUGH 64 YEARS OF AGE

Recruiting· BioNTech logo

BioNTech·Approved·NCT07730450·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for BNT162b2 vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BNT162b2 vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BNT162b2 vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: BioNTech

BNT162b2 vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

COVID-196 trials

Trial1 trial

COVID-19 Vaccine1 trial

References

Drug Info

Quick Facts

Related News